The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,336.00
Bid: 12,334.00
Ask: 12,338.00
Change: 4.00 (0.03%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,374.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI) - AstraZeneca Plc -Amendment

21 May 2014 14:49

RNS Number : 7253H
J.P. Morgan Securities LLC
21 May 2014
 



AMENDMENT

CHANGED POSITION FROM 46,106 TO ZERO

 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

AstraZeneca Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc.

(d) Date position held/dealing undertaken:

19 May 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

NO

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00%

(2) Derivatives (other than options):

(3) Options and agreements to purchase/sell:

 

TOTAL:

 

0

 

0.00%

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

(USD)

Ordinary Shares traded as ADRs

Purchases

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

 

 

 

 

 

1,000

400

300

1,225

100

100

2,177

960

1,000

1,000

100

100

100

100

100

300

28,200

610

300

521

150

100

12,000

100

3,200

7,850

2,800

400

21,700

5,966

2,600

2,400

28,800

101,124

4,600

2,450

600

100

2,200

1,300

100

700

700

2,500

400

2,200

2,600

800

500

200

400

100

500

1,600

800

600

2,100

6,672

4,800

5,600

600

1,000

7,412

2,120

700

2,698

1,302

100

9,500

1,457

1,500

100

902

602

1,100

1,000

100

1,250

650

1,200

916

500

400

4,001

2,700

1,000

100

400

600

500

2,750

1,051

499

400

500

1,000

4

1,000

1,000

7,564

2,600

1,602

700

190

10,710

2,500

2,500

300

300

1,400

1,200

2,775

4,152

725

123

75,756

5,400

800

9,400

2,700

19,300

4,941

100

3,800

4,322

1,550

13,023

2,432

50,000

25,450

13,155

1,700

1,000

8,256

6,600

600

1,700

2,000

3,515

3,075

1,860

2,000

150

2,000

4,201

12,600

1,300

100

2,178

200

300

54,210

40,500

1,300

100

2,300

25

1,800

1,900

1,200

600

202

830

2,600

600

4,200

1,000

2

1,200

137

2,465

2,535

100,000

500

1,800

200

21,700

5,966

2,600

1,500

102,274

4,600

950

400

1,600

1,912

2,100

1,700

400

1,300

2,000

800

500

200

1,100

800

200

2,100

6,448

4,400

5,600

400

7,012

200

300

698

1,302

100

9,500

1,200

400

100

800

200

500

700

100

5,050

150

616

100

3,000

2,600

900

400

1,000

500

700

3,863

400

1,300

100

1,601

6,651

300

5,568

380

1,020

1,000

6,400

2,600

1,602

700

190

5,694

3,501

400

300

100

3,200

100

300

115

4,152

725

123

79,731

3,400

100

200

9,700

300

2,800

700

19,300

3,300

500

4,500

100

2,400

900

15,056

100

4,532

50,300

17,052

100

10,155

1,700

1,000

8,256

6,600

600

1,700

3,515

3,075

1,860

2,000

150

400

300

1,750

2,000

4,951

4,200

1,300

400

100

300

1,200

2,478

200

300

25,700

12,300

1,000

37,432

1,700

2,400

100

1,100

500

600

11,800

2,100

3,900

1,200

500

3,200

600

8,898

702

3,300

700

600

1,000

100

200

100

 

70.1100

70.1600

70.1900

70.2100

70.3400

70.3500

70.3600

70.3700

70.3900

70.4000

70.4200

70.4600

70.5400

70.6000

70.7500

70.8400

70.8500

70.8600

70.8700

70.8800

70.8900

70.8975

70.9000

70.9025

70.9050

70.9100

70.9300

70.9400

71.0100

71.0200

71.0300

71.0301

71.0400

71.0500

71.0600

71.0700

71.0800

71.0875

71.0900

71.1000

71.1075

71.1100

71.1200

71.1300

71.1400

71.1500

71.1600

71.1700

71.1800

71.1900

71.2000

71.2175

71.2200

71.2300

71.2400

71.2500

71.2600

71.2800

71.2900

71.3000

71.3100

71.3300

71.3400

71.3500

71.3600

71.3700

71.3800

71.3900

71.4000

71.4100

71.4200

71.4300

71.4400

71.4500

71.4600

71.4700

71.4800

71.4900

71.5000

71.5075

71.5100

71.5200

71.5275

71.5300

71.5400

71.5500

71.5575

71.5600

71.5700

71.5775

71.5800

71.5900

71.6000

71.6100

71.7500

71.7700

71.8000

71.8300

71.8900

71.9000

71.9100

71.9200

71.9300

71.9400

71.9500

71.9600

71.9700

72.0400

72.0450

72.0500

72.0800

72.0900

72.1300

72.1400

72.1600

72.1700

72.1800

72.2000

72.2200

72.2400

72.2700

72.2800

72.2900

72.3000

72.3100

72.3200

72.3300

72.3400

72.3500

72.3600

72.3700

72.3800

72.3900

72.4000

72.4200

72.4400

72.4500

72.4600

72.5000

72.5100

72.5200

72.5300

72.5400

72.6100

72.6200

72.6300

72.6400

72.6500

72.7100

72.7150

72.7200

73.0000

73.0815

73.3000

73.3200

73.3300

73.4400

73.4500

73.4700

73.5500

73.5700

73.8100

73.8200

73.8300

73.9600

74.0000

74.0200

74.2100

74.2200

 

70.6450

70.6500

70.6550

70.8500

70.8600

70.9300

70.9400

71.0100

71.0200

71.0300

71.0400

71.0500

71.0600

71.0700

71.0800

71.0900

71.1000

71.1200

71.1300

71.1400

71.1500

71.1600

71.1700

71.1800

71.1900

71.2300

71.2400

71.2500

71.2600

71.2800

71.2900

71.3000

71.3100

71.3400

71.3500

71.3600

71.3700

71.3800

71.3900

71.4000

71.4100

71.4200

71.4300

71.4400

71.4500

71.4600

71.4700

71.4800

71.4900

71.5000

71.5100

71.5200

71.5300

71.5400

71.5500

71.5600

71.5700

71.5800

71.6500

71.7500

71.7550

71.7600

71.7650

71.7700

71.7800

71.7900

71.8000

71.8200

71.8300

71.8900

71.9000

71.9100

71.9200

71.9300

71.9400

71.9500

71.9600

71.9700

71.9900

72.0400

72.0700

72.0750

72.0800

72.0900

72.1300

72.1400

72.1600

72.1700

72.1800

72.2000

72.2100

72.2200

72.2300

72.2400

72.2600

72.2700

72.2800

72.2900

72.3000

72.3050

72.3100

72.3200

72.3300

72.3350

72.3400

72.3500

72.3600

72.3650

72.3700

72.3800

72.3900

72.4000

72.4200

72.4400

72.4500

72.5000

72.5100

72.5200

72.5300

72.5400

72.5700

72.5900

72.6000

72.6100

72.6200

72.6300

72.6400

72.6500

72.6900

72.6950

72.7000

72.7100

72.7150

72.7200

72.9500

72.9600

72.9700

73.0000

73.0100

73.0200

73.0300

73.0400

73.0500

73.0600

73.0700

73.0800

73.0900

73.1000

73.1100

73.1300

73.1400

73.1500

73.1600

73.1700

73.1800

73.1900

73.5200

73.5300

73.5400

73.5600

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

21 May 2014

Contact name:

Michael Kirwan

Telephone number:

020 7134 6153

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEODMGZKFMNGDZM
Date   Source Headline
7th May 20247:00 amRNSAstraZeneca completes Cellectis equity investment
2nd May 20247:00 amRNSCalquence combination improved PFS in 1L MCL
1st May 20243:00 pmRNSTotal Voting Rights
29th Apr 20247:05 amRNSTruqap recommended for EU breast cancer approval
29th Apr 20247:00 amRNSEnhertu improved PFS in HER2-low and ultralow
25th Apr 20247:00 amRNS1st Quarter Results
11th Apr 20245:30 pmRNSResult of AGM
11th Apr 20247:00 amRNSAstraZeneca increases 2024 dividend by 7%
8th Apr 20247:00 amRNSEnhertu approved in US for HER2+ solid tumours
5th Apr 20247:00 amRNSImfinzi improved OS & PFS in limited-stage SCLC
2nd Apr 20243:00 pmRNSTotal Voting Rights
2nd Apr 20247:05 amRNSVoydeya approved in US
2nd Apr 20247:00 amRNSFDA accepts Dato-DXd BLA for breast cancer
25th Mar 20247:00 amRNSUltomiris approved in the US for NMOSD
19th Mar 20247:00 amRNSAstraZeneca to acquire Fusion
14th Mar 20247:00 amRNSAstraZeneca to acquire Amolyt
12th Mar 202411:00 amRNSDirector/PDMR Shareholding
7th Mar 202411:00 amRNSNotice of AGM
6th Mar 20243:05 pmRNSDirector/PDMR Shareholding
6th Mar 20243:00 pmRNSDirector/PDMR Shareholding
4th Mar 20247:00 amRNSEMA validates Dato-DXd MAAs for NSQ NSCLC and BC
1st Mar 20243:00 pmRNSTotal Voting Rights
26th Feb 20247:00 amRNSVoydeya recommended for EU approval
22nd Feb 20241:15 pmRNSAcquisition of Gracell completed
22nd Feb 202411:00 amRNSDirector/PDMR Shareholding
22nd Feb 20247:00 amRNSAstraZeneca prices a $5bn bond offering
21st Feb 20247:00 amRNSFiling of Form 20-F with SEC
20th Feb 202411:00 amRNSAnnual Financial Report
19th Feb 20243:00 pmRNSAstraZeneca completes acquisition of Icosavax
19th Feb 20247:10 amRNSTagrisso plus chemo approved in US for lung cancer
19th Feb 20247:05 amRNSFDA accepts Dato-DXd BLA for nonsquamous NSCLC
19th Feb 20247:00 amRNSTagrisso improved PFS in Stage III lung cancer
8th Feb 20247:00 amRNSFinal Results
1st Feb 20243:00 pmRNSTotal Voting Rights
2nd Jan 20243:00 pmRNSTotal Voting Rights
27th Dec 20237:00 amRNSAstraZeneca acquires Gracell
22nd Dec 20237:00 amRNSWainua (eplontersen) granted first US FDA approval
14th Dec 20233:00 pmRNSDirector/PDMR Shareholding
12th Dec 20237:05 amRNSAstraZeneca to acquire Icosavax
1st Dec 20233:05 pmRNSBlock listing Interim Review
1st Dec 20233:00 pmRNSTotal Voting Rights
1st Dec 20237:00 amRNSDiscontinuation of two CRYSTALIZE evidence trials
23rd Nov 20233:00 pmRNSDirector/PDMR Shareholding
17th Nov 20237:00 amRNSTruqap approved in US for HR+ breast cancer
14th Nov 20237:05 amRNSUpdate on PACIFIC-2 Phase III trial for Imfinzi
9th Nov 20233:00 pmRNSDirector Declaration
9th Nov 20237:10 amRNSImfinzi combination improves PFS in liver cancer
9th Nov 20237:05 amRNSAgreement with Eccogene for clinical stage GLP-1RA
9th Nov 20237:00 amRNS9M and Q3 2023 results
1st Nov 20233:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.